Lisinopril Dihydrate: Long-Acting ACE Inhibitor for Hypertension Research

Executive Summary: Lisinopril dihydrate (SKU B3290, APExBIO) is a commercially available dihydrate form of lisinopril, a lysine-based, long-acting ACE inhibitor with an IC₅₀ of 4.7 nM under standard assay conditions (APExBIO product page). It selectively inhibits angiotensin converting enzyme (ACE), reducing the conversion of angiotensin I to angiotensin II, resulting in decreased blood pressure via vasodilation and reduced aldosterone secretion (Tieku & Hooper 1992). Lisinopril dihydrate is highly soluble in water (≥2.46 mg/mL with warming/ultrasonication), stable at room temperature, and is available at ≥98% purity verified by mass spectrometry and NMR. The compound is widely used as a benchmark tool in hypertension, heart failure, myocardial infarction, and nephropathy research (see comparative analysis).

Biological Rationale

Angiotensin converting enzyme (ACE; EC 3.4.15.1) is a zinc-dependent metallopeptidase that catalyzes the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. ACE also degrades bradykinin, a vasodilator peptide, thus modulating vascular tone and fluid homeostasis (Tieku & Hooper 1992). Dysregulation of the renin-angiotensin system (RAS) is a central mechanism in the pathogenesis of hypertension, heart failure, and progressive kidney disease. Selective inhibition of ACE reduces angiotensin II and aldosterone levels while increasing plasma renin activity and bradykinin concentrations, leading to antihypertensive and organ-protective effects. Lisinopril dihydrate, as a lysine analogue of MK 421, is designed for high affinity and prolonged inhibition of ACE, facilitating both acute and chronic research models. Its specificity ensures minimal interference with other cell surface peptidases, a critical requirement for mechanistic studies (Molecular Precision in Peptidase-Targeting).

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate binds competitively to the active site of ACE, chelating the active site zinc ion. This interaction prevents the enzymatic conversion of angiotensin I (a decapeptide) to angiotensin II (an octapeptide), thereby blunting vasoconstriction and aldosterone secretion (Tieku & Hooper 1992). The inhibition constant (IC₅₀) of 4.7 nM was determined under buffered conditions at 37°C, pH 8.3, using a synthetic substrate. Lisinopril does not significantly inhibit aminopeptidase N (CD13), aminopeptidase A, or aminopeptidase W, demonstrating high selectivity among mammalian cell surface peptidases. The result is decreased plasma angiotensin II, reduced aldosterone, increased plasma renin, and enhanced bradykinin action. The vasodilatory effect is accompanied by reduced sodium and water retention, lowering systemic vascular resistance and blood pressure. Lisinopril’s dihydrate form improves solubility and handling for laboratory workflows (product details).

Evidence & Benchmarks

• Lisinopril dihydrate exhibits an IC₅₀ of 4.7 nM for ACE inhibition in vitro (Tieku & Hooper 1992, https://doi.org/10.1016/0006-2952(92)90065-Q).
• It does not significantly inhibit aminopeptidase N, aminopeptidase A, or aminopeptidase W at concentrations selective for ACE inhibition (Tieku & Hooper 1992, https://doi.org/10.1016/0006-2952(92)90065-Q).
• In water, lisinopril dihydrate is soluble to ≥2.46 mg/mL with gentle warming and sonication (APExBIO, https://www.apexbt.com/lisinopril-dihydrate.html).
• Purity of ≥98% is confirmed by MS and NMR, ensuring batch-to-batch reproducibility (APExBIO, https://www.apexbt.com/lisinopril-dihydrate.html).
• Lisinopril dihydrate is validated for use in hypertension, heart failure, myocardial infarction, and diabetic nephropathy models (see Strategic ACE Inhibition Guide for advanced protocols).

Applications, Limits & Misconceptions

Lisinopril dihydrate is primarily used in preclinical and translational research targeting the renin-angiotensin pathway. It is suitable for both acute and chronic dosing regimens, as well as cell-based and in vivo models. Its molecular precision supports mechanistic dissection of blood pressure regulation and end-organ protection. For protocol guidance, see the Advanced ACE Inhibitor Protocols; this article extends those protocols by detailing solubility, storage, and purity standards for reproducible outcomes.

Common Pitfalls or Misconceptions

• Lisinopril dihydrate does not inhibit non-ACE metallopeptidases at physiologically relevant concentrations, so it cannot be used as a pan-metallopeptidase inhibitor (Tieku & Hooper 1992).
• It is not suitable for ethanol-based assays due to insolubility in ethanol (APExBIO).
• Long-term storage of aqueous solutions is not recommended—prepare fresh aliquots to maintain activity (APExBIO guidelines).
• Lisinopril dihydrate is not a clinical-grade pharmaceutical; it is intended for research use only.
• It cannot be used to selectively probe aminopeptidase N, A, or W biology, as it lacks potency for these enzymes (Tieku & Hooper 1992).

Workflow Integration & Parameters

Lisinopril dihydrate (B3290) is supplied as a solid, with a molecular weight of 441.52 g/mol and chemical formula C₂₁H₃₅N₃O₇. Reconstitute in water to at least 2.46 mg/mL using gentle warming (37°C) and ultrasonic treatment if necessary. Avoid ethanol as a solvent. For maximal stability, store dry powder desiccated at room temperature; avoid repeated freeze-thaw cycles for solutions. APExBIO ships the product on blue ice to preserve integrity during transit. Purity is supported by lot-specific Certificate of Analysis and analytical QC data. For reliable results in cell-based or animal studies, refer to the cell assay troubleshooting guide, which this article updates by incorporating advanced purity and solubility specifications.

Conclusion & Outlook

Lisinopril dihydrate is a validated, highly selective ACE inhibitor with robust physicochemical and biological credentials. It is a preferred tool for probing the renin-angiotensin system in cardiovascular and renal research, providing consistent results across diverse experimental models. APExBIO's high-purity standard and transparent documentation support its integration into advanced hypertension and organ protection studies. Future work will likely expand on structure-guided optimization and multi-target RAS blockade, but for now, lisinopril dihydrate remains a gold standard for mechanism-driven ACE inhibition.